CA
NZ
UK
AU
IND
US
• The stock's rally follows a blockbuster first-quarter 2026 earnings beat, with revenue of $19.8 billion, up 55.5% year over year.
• AstraZeneca entered a new collaboration with CSPC Pharmaceutical Group for siRNA-based drug candidates worth up to $570 million.
• The European Commission granted marketing authorization for Itvisma, a gene replacement therapy for spinal muscular atrophy.
• The move was driven by broader biotech sector momentum rather than company-specific news.
• A fresh £100 million buyback tranche launched July 1, running through July 21.
• The company secured dual positive CHMP opinions for RINVOQ in severe alopecia areata and non-segmental vitiligo.
• First-quarter earnings per share reached $2.70 on revenue of $24.06 billion, up 9.9% year over year.
• The company reported securing lower raw material prices from suppliers to stay competitive in the weight-loss drug market.
• The stock remains roughly 68% below its May registered-direct offering price of $20.30.
• Shared umbrella with BLKIF: IAACF trades under the same iShares IV PLC structure as BLKIF, though the two represent distinct underlying funds.
Please wait processing your request...